Form D · Biotechnology
Anogen Life Sciences, Inc.
St. Petersburg, FL · CIK 0001800417
Offering snapshot reported Feb 5, 2021 · SEC filing
- Reported sold
- $408K Offering amount: $408K
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 27, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 5, 2021 | Initial | $407,600 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-388554
Source: Form D, filed Feb 5, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Adair | Director |
| Steven B. Bettis | Director, Executive |
| Andreas Reiff | Director |
| Seth Yakatan | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7901 4th Street N, Suite 300
St. Petersburg, FL, 33702
St. Petersburg, FL, 33702